Inhibition of GSK-3β restores delayed gastric emptying in obesity-induced diabetic female mice

Am J Physiol Gastrointest Liver Physiol. 2020 Oct 1;319(4):G481-G493. doi: 10.1152/ajpgi.00227.2020. Epub 2020 Aug 19.

Abstract

Diabetic gastroparesis (DG) is a clinical syndrome characterized by delayed gastric emptying (DGE). Loss of nuclear factor erythroid 2-related factor 2 (Nrf2) is associated with reduced neuronal nitric oxide synthase-α (nNOSα)-mediated gastric motility and DGE. Previous studies have shown that nuclear exclusion and inactivation of Nrf2 is partly regulated by glycogen synthase kinase 3β (GSK-3β). In the current study, the molecular signaling of GSK-3β-mediated Nrf2 activation and its mechanistic role on DG were investigated in high-fat diet (HFD)-induced obese/Type 2 diabetes (T2D) female mice. Adult female C57BL/6J mice were fed with HFD or normal diet (ND) with or without GSK-3β inhibitor (SB 216763, 10 mg/kg body wt ip) start from the 14th wk and continued feeding mice for an additional 3-wk time period. Our results show that treatment with GSK-3β inhibitor SB attenuated DGE in obese/T2D mice. Treatment with SB restored impaired gastric 1) Nrf2 and phase II antioxidant enzymes through PI3K/ERK/AKT-mediated pathway, 2) tetrahydrobiopterin (BH4, cofactor of nNOS) biosynthesis enzyme dihydrofolate reductase, and 3) nNOSα dimerization in obese/T2 diabetic female mice. SB treatment normalized caspase 3 activity and downstream GSK-3β signaling in the gastric tissues of the obese/T2 diabetic female mice. In addition, GSK-3β inhibitor restored impaired nitrergic relaxation in hyperglycemic conditions. Finally, SB treatment reduced GSK3 marker, pTau in adult primary enteric neuronal cells. These findings emphasize the importance of GSK-3β on regulating gastric Nrf2 and nitrergic mediated gastric emptying in obese/diabetic rodents.NEW & NOTEWORTHY Inhibition of glycogen synthase kinase 3β (GSK-3β) with SB 216763 attenuates delayed gastric emptying through gastric nuclear factor erythroid 2-related factor 2 (Nrf2)-phase II enzymes in high-fat diet-fed female mice. SB 216763 restored impaired gastric PI3K/AKT/ β-catenin/caspase 3 expression. Inhibition of GSK-3β normalized gastric dihydrofolate reductase, neuronal nitric oxide synthase-α expression, dimerization and nitrergic relaxation. SB 216763 normalized both serum estrogen and nitrate levels in female obese/Type 2 diabetes mice. SB 216763 reduced downstream signaling of GSK-3β in enteric neuronal cells in vitro.

Keywords: BH4; GSK-3β; Nrf2; gastric emptying; nNOS.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antioxidants / physiology
  • Diabetes Mellitus, Experimental / etiology
  • Diabetes Mellitus, Experimental / physiopathology*
  • Diabetes Mellitus, Type 2 / complications
  • Diet, High-Fat
  • Female
  • Gastric Emptying / drug effects*
  • Gastric Emptying / physiology
  • Gastroparesis / drug therapy*
  • Gastroparesis / etiology
  • Glucose / metabolism
  • Glycogen Synthase Kinase 3 beta / antagonists & inhibitors*
  • Glycogen Synthase Kinase 3 beta / physiology
  • Indoles / pharmacology*
  • Insulin Resistance / physiology
  • Maleimides / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • NF-E2-Related Factor 2 / drug effects
  • Nitric Oxide Synthase Type I / drug effects
  • Obesity / complications*
  • Obesity / etiology

Substances

  • Antioxidants
  • Indoles
  • Maleimides
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, mouse
  • SB 216763
  • Nitric Oxide Synthase Type I
  • Nos1 protein, mouse
  • Glycogen Synthase Kinase 3 beta
  • Glucose